Middle East And Africa Ophthalmology Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 2,071.55 Million |
 Taille du marché (année de prévision) |
USD 2,971.09 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché de l'ophtalmologie au Moyen-Orient et en Afrique, par produit (dispositif, médicaments et autres), maladies (glaucome, cataracte, dégénérescence maculaire liée à l'âge, maladies inflammatoires, troubles de la réfraction et autres), mode de prescription (générique et de marque), type de médicament (sur ordonnance et en vente libre), voie d'administration (orale, topique, injectables, oculaire locale et autres), utilisateur final (hôpitaux, cliniques, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché de l'ophtalmologie au Moyen-Orient et en Afrique
L'un des principaux facteurs à l'origine de la croissance du marché de l'ophtalmologie est la prévalence croissante des troubles ophtalmiques et des douleurs oculaires. Les recherches cliniques continues menées par plusieurs entreprises pharmaceutiques pour améliorer les choix de traitement et l'exposition à certaines toxines ou changements environnementaux augmentent la fréquence des produits ophtalmologiques et conduisent à l'expansion du marché. Le marché est également influencé par des modes de vie de plus en plus insalubres et sédentaires et par une augmentation des blessures traumatiques. Cependant, le coût élevé et les risques associés à la chirurgie et au traitement oculaires, le manque d'assurance maladie au sein de la population, en particulier dans les pays en développement, et la période prolongée de fabrication et de formulation des médicaments ophtalmiques constituent des facteurs restrictifs pour le marché de l'ophtalmologie au Moyen-Orient et en Afrique au cours de la période de prévision.
Le marché de l'ophtalmologie au Moyen-Orient et en Afrique devrait connaître une croissance de marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 4,6 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 2 971,09 millions USD d'ici 2030, contre 2 071,55 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type de produit (dispositif, médicaments et autres), maladies ( glaucome , cataracte, dégénérescence maculaire liée à l'âge, maladies inflammatoires, troubles de la réfraction et autres), mode de prescription (générique et de marque), type de médicament (sur ordonnance et en vente libre (OTC)), voie d'administration (orale, topique, injectables, oculaire locale et autres), utilisateur final (hôpitaux, cliniques, soins de santé à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël, Koweït et le reste du Moyen-Orient et de l’Afrique. |
|
Acteurs du marché couverts |
Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Ziemer Ophthalmic Systems AG, among others. |
Market Definition
Ophthalmology is a branch of medicine that deals with the anatomy, physiology, treatment and surgery of the visual pathways of the eye, including surrounding areas and the visual aspects of the brain. Ophthalmic devices are medical equipment designed for surgery, diagnosis, and vision correction. The devices gained increased importance and adoption due to the high prevalence of several ophthalmic diseases, such as glaucoma, cataract, and other vision-related issues. Ophthalmic drugs are medications that are specially designed and administered for the treatment of various eye-related disorders, including color blindness, diabetic macular edema, cytomegalovirus (CMV), and age-related macular degeneration (AMD).
Ophthalmology Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising prevalence of ophthalmic disorders & ocular pains
Ophthalmic disorders are the vital cause of major ocular and orbital pains in the eye. Ocular pain occurs over the surface of the eyes along with symptoms such as scratching, burning, or itching sensation. This may be due to multiple reasons, including irritation from foreign objects, infection or trauma. Eyelashes or pieces of dirt, smoke, dust or some harsh eye cosmetics are the common causes leading to ocular pain, redness, and watery eyes.
The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area. The affirmative factor states that this is the major driver for the Middle East and Africa ophthalmology market.
- Rise in traumatic injuries
Traumatic head injury is one of the causes of such disorders as optic nerve disorders. A traumatic injury is a physical injury that occurs suddenly with a certain degree of severity. Trauma can be caused by a variety of external injuries. The most common causes of traumatic injury include road accidents, sports injuries, and violence, among others which can lead to some serious eye disorders as well. The prevalence of such traumatic injuries is highly seen worldwide.
Hence, such traumatic injuries lead to optic nerve disorders, which are affecting the population in these years and it is increasing with the rising population. Therefore, a rise in traumatic injuries is expected to drive market growth.
Opportunities
-
Rise in healthcare expenditure and disposable income
Healthcare expenditure and its growth rate over time are inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system.
Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by virtue of accelerating healthcare expenditure.
Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth. It is primarily fruitful as it significantly affects the development of better and more advanced medical products in the market. Therefore, the surge in healthcare expenditure may act as a great opportunity for market growth.
-
Rising awareness to prevent the burden of eye diseases
Significant advancements in the prevention of visual impairment have been made to battle visible diseases by various organizations such as World Health Organization (WHO) and its Member States, UN agencies, Non-Governmental Organizations (NGOs) and the private sector. Therefore, the second Thursday of October is World Sight Day (WSD), an annual awareness day to create Middle East and Africa attention on blindness and vision impairment.
Thus, the programs and initiatives to reduce the burden of eye diseases are expected to create opportunities for the growth of the Middle East and Africa ophthalmology market in the forecast period.
Restraints/Challenges
- High cost & risks associated with eye surgery & treatment
The cost of the various disorders treatment plays a major role in the market. The optic nerve disorders treatments are highly sophisticated, as the prevalence of such disorders is increasing; hence the need for such products has eventually raised, thereby raising the treatment cost, which can hinder the market growth in the coming years.
There are various methods for the treatment of optic neuritis disorder. Some of them are patients can take various medicines such as corticosteroids like methylprednisolone, prednisone, immunoglobulin, vitamin B12 shots and various other surgeries. With these, there are some of the risks associated with it.
Therefore, for some of the population around the country, it is difficult for them to undergo such treatments due to the high cost. Hence, the high cost associated with ophthalmic disorders treatment is expected to restrain market growth.
- Lack of skilled professionals
The number of ophthalmologists in both emerging and industrialized countries is minor. However, projections are a little higher for developing countries. The number of ophthalmologists is cumulative but not as fast as the population of elderly patients aged 60 years or older who need to be amplified ophthalmologic care. In most countries, the problem is that demographic changes do not match up with professional development. It is required to train eye care teams to meet the current number of ophthalmologists worldwide. The increased need for ophthalmologists globally also reflects an increase in the cases of diabetes. Diabetic patients should get their eyes inspected every year. The increasing demand for ophthalmologists is directly proportional to the growing geriatric population since eye care is an integral part of healthcare. The access to care gaps can be met by combining factors, including more efficient practice structures, processes and appropriate use of technology.
Post-COVID-19 Impact on the Ophthalmology market
The COVID-19 pandemic had a great impact on the ophthalmology and surgical industries. Trade groups in the ophthalmic and vision products sector claim that the Middle East and Africa supply chain for operating, diagnostic and vision care products has been significantly damaged, impacting end-user consumption of the ophthalmology market. Sales of vision care products in the first quarter of 2020 were significantly delayed due to logistical and transportation issues. On the demand side, the market is increasing as people have to get operated after the lockdown scenario. The situation needs to be taken into consideration, and emergency operations need to be operated. Furthermore, on the supply side, the growth of the market is on a negative scale. This is due to the lockdown situations in many countries manufacturing diagnostic, operating and vision care instruments.
Recent Developments
- In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others
- In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience
Middle East and Africa Ophthalmology Market Scope
The Middle East and Africa ophthalmology market is segmented into products, disease, prescription mode, drug type, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Products
- Device
- Drugs
- Others
On the basis of products, the ophthalmology market is segmented into devices, drugs, and others.
Diseases
- Glaucoma
- Cataract
- Age-Related Macular Degeneration
- Inflammatory Diseases
- Refractive Disorders
- Others
On the basis of diseases, the ophthalmology market is segmented into glaucoma, cataracts, age-related macular degeneration, inflammatory diseases, refractive disorders, and others.
Prescription Mode
- Generic
- Branded
On the basis of prescription mode, the ophthalmology market is segmented into generic and branded.
Drug Type
- Prescription
- Over the Counter (OTC)
On the basis of drug type, the ophthalmology market is segmented into prescription and over-the-counter (OTC).
Route of Administration
- Oral
- Topical
- Injectables
- Local Ocular
- Others
On the basis of route of administration, the ophthalmology market is segmented into oral, topical, injectables, local ocular and others.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the ophthalmology market is segmented into hospitals, clinics, home healthcare, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channels, the ophthalmology market is segmented into direct tender, retail sales, and others.
Ophthalmology Market Regional Analysis/Insights
The Middle East and Africa gaskets market is segmented on the basis of products, disease, prescription mode, drug type, route of administration, end user, and distribution channel.
The countries in the Middle East and Africa gaskets market are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and Rest of the Middle East and Africa.
South Africa is increasing because of increase in demand for ophthalmology products and an increase in research and development activities in the industry are also expected to drive the market in the forecasted period.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data point downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Ophthalmology Market Share Analysis
Le paysage concurrentiel du marché de l'ophtalmologie fournit des détails par concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que les entreprises se concentrant sur le marché de l'ophtalmologie au Moyen-Orient et en Afrique.
Français Certains des principaux acteurs opérant sur ce marché sont Alcon, Regeneron Pharmaceuticals Inc., Johnson & Johnson, Inc., Novartis AG, Bausch & Lomb Incorporated, HOYA Corporation., The Cooper Companies Inc., Santen Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, Carl Zeiss Meditec AG, AbbVie Inc., EssilorLuxottica, NIDEK CO., LTD., TOPCON CORPORATION, Glaukos Corporation., STAAR SURGICAL, Metall Zug AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc. et Ziemer Ophthalmic Systems AG, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 STRATEGIC INITIATIVES
7 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, REGULATION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE
8.1.3 RISE IN TRAUMATIC INJURIES
8.1.4 RISE IN THE GERIATRIC POPULATION
8.2 RESTRAINTS
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS
8.3 OPPORTUNITIES
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES
8.4 CHALLENGE
8.4.1 LACK OF SKILLED PROFESSIONALS
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL
9 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY PRODUCTS
9.1 OVERVIEW
9.2 DEVICE
9.2.1 SURGICAL DEVICE
9.2.1.1 CATARACT SURGICAL DEVICES
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES
9.2.1.2.1 PHACOEMULSIFICATION DEVICES
9.2.1.2.2 CATARACT SURGICAL LASERS
9.2.1.2.3 IOL INJECTORS
9.2.1.3 VITREORETINAL SURGICAL DEVICES
9.2.1.3.1 VITREORETINAL PACKS
9.2.1.3.2 VITRECTOMY MACHINES
9.2.1.3.3 VITRECTOMY PROBES
9.2.1.3.4 PHOTOCOAGULATION LASERS
9.2.1.3.5 ILLUMINATION DEVICES
9.2.1.4 REFRACTIVE SURGICAL DEVICES
9.2.1.4.1 FEMTOSECOND LASERS
9.2.1.4.2 EXCIMER LASERS
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS
9.2.1.5 GLAUCOMA SURGICAL DEVICES
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES
9.2.1.5.2 GLAUCOMA LASER SYSTEMS
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES
9.2.2 DIAGNOSTIC DEVICE
9.2.2.1 AUTOREFRACTORS & KERATOMETERS
9.2.2.2 TONOMETER
9.2.2.3 PHOROPTERS
9.2.2.4 RETINOSCOPES
9.2.2.5 OPHTHALMOSCOPES
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
9.2.2.7.1 A- SCAN IMAGING SYSTEM
9.2.2.7.2 B-SCAN IMAGING SYSTEM
9.2.2.7.3 PACHYMETERS
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES
9.2.2.8 LENSMETERS
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
9.2.2.11 FUNDUS CAMERAS
9.2.2.12 OPTICAL BIOMETRY SYSTEMS
9.2.2.13 SPECULAR MICROSCOPES
9.2.2.14 WAVEFRONT ABERROMETERS
9.2.2.15 CHART PROJECTORS
9.2.2.16 SLIT LAMPS
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES
9.2.3.1 SURGICAL INSTRUMENTS & KITS
9.2.3.2 OPHTHALMIC FORCEPS
9.2.3.3 OPHTHALMIC SPATULA
9.2.3.4 OPHTHALMIC TIPS AND HANDLES
9.2.3.5 OPHTHALMIC CANNULAS
9.2.3.6 OPHTHALMIC SCISSORS
9.2.3.7 OTHERS SURGICAL ACCESSORIES
9.2.4 OPHTHALMIC MICROSCOPES
9.3 DRUGS
9.3.1 ANTI-INFLAMMATION DRUGS
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS
9.3.2 ALLERGIC CONJUNCTIVITIS
9.3.3 DRY EYE DRUGS
9.3.4 RETINAL DISORDER DRUGS
9.3.5 ANTI-GLAUCOMA DRUGS
9.3.5.1 MIOTICS
9.3.5.1.1 PILOCARPINE
9.3.5.1.2 ESERINE
9.3.5.2 BETA ADRENERGIC ANTAGONISTS
9.3.5.2.1 TIMOLAL MALEATE
9.3.5.2.2 BETAXOLOL
9.3.5.3 PROSTAGLANDIN ANALOGS
9.3.5.3.1 LATANOPROST
9.3.5.3.2 BIMATOPROST
9.3.5.3.3 TRAVOPROST
9.3.5.3.4 TAFLUPROST
9.3.5.3.5 LATANOPROSTENE
9.3.5.4 ALPHA ADRENERGIC AGONISTS
9.3.5.4.1 EPINEPHRINE
9.3.5.4.2 DEPIVEPRINE
9.3.5.5 ANTI-VEGF DRUGS
9.3.5.5.1 RANIBIZUMAB
9.3.5.5.2 BEVACIZUMAB
9.3.6 OTHERS
9.4 OTHERS
9.4.1 VISION CARE PRODUCTS
9.4.1.1 SPECTACLES
9.4.1.2 CONTACT LENSES
9.4.1.2.1 SOFT CONTACT LENSES
9.4.1.2.2 HYBRID CONTACT LENSES
9.4.1.2.3 RIGID GAS PERMEABLE LENSES
9.4.2 OTHERS
10 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DISEASES
10.1 OVERVIEW
10.2 INFLAMMATORY DISEASES
10.3 CATARACT
10.4 REFRACTIVE DISORDERS
10.5 GLAUCOMA
10.6 AGE-RELATED MACULAR DEGENERATION
10.7 OTHERS
11 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE
11.1 OVERVIEW
11.2 BRANDED
11.3 GENERIC
12 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 TOPICAL
13.2.1 EYE DROPS
13.2.2 EYE SOLUTION
13.2.3 CREAM & OINTMENTS
13.2.4 GEL
13.2.5 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 LOCAL OCULAR
13.4.1 SUBCONJUNCTIVAL
13.4.2 INTRAVITREAL
13.4.3 RETROBULBAR
13.4.4 INTRACAMERAL
13.5 INJECTABLE
13.5.1 INTRAMUSCULAR
13.5.2 INTRAVENOUS
13.5.3 OTHERS
13.6 OTHERS
14 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY END USER
14.1 OVERVIEW
14.2 CLINICS
14.3 HOSPITALS
14.4 HOMECARE SETTINGS
14.5 OTHERS
15 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 RETAIL SHOPS
15.2.2 HOSPITAL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
15.4 OTHERS
16 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY GEOGRAPHY
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 U.A.E.
16.1.4 EGYPT
16.1.5 KUWAIT
16.1.6 ISRAEL
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 ALCON
19.1.1 COMPANY SNAPSHOT
19.1.2 RECENT FINANCIALS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 REGENERON PHARMACEUTICALS INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 RECENT FINANCIALS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 JOHNSON & JOHNSON SERVICES, INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 RECENT FINANCIALS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 REICHERT, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ABBVIE INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 RECENT FINANCIALS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BAUSCH & LOMB INCORPORATED
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CARL ZEISS MEDITEC AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ESSILORLUXOTTICA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMEN
19.1 F. HOFFMANN- LA ROCHE LTD
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 GLAUKOS
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 HEIDELBERG ENGINEERING GMBH
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HOYA CORPORATION
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 LUMENIS BE LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 METALL ZUG AG
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 NEOVISION
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 NIDEK CO., LTD.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SANTEN PHARMACEUTICAL CO., LTD.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT FINANCIALS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 RECENT FINANCIALS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 STAAR SURGICAL
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 THE COOPER COMPANIES INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TOPCON CORPORATION
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 VISIONIX
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 ZIEMER OPHTHALMIC SYSTEMS AG
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA DEVICE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA DRUGS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA ANTI INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA ANTI GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION))
TABLE 25 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DISEASES 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA INFLAMMATORY DISEASES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA CATARACT IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA REFRACTIVE DISORDERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA GLAUCOMA IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA BRANDED IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA GENERIC IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DRUG TYPE 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA OVER THE COUNTER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA PRESCRIPTION IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA TOPICAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA ORAL IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA CLINICS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA HOSPITALS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA HOME HEALTHCARE IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA DIRECT TENDER IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 92 SOUTH AFRICA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 93 SOUTH AFRICA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 94 SOUTH AFRICA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 95 SOUTH AFRICA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 96 SOUTH AFRICA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 97 SOUTH AFRICA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 SOUTH AFRICA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 SOUTH AFRICA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 SOUTH AFRICA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 SOUTH AFRICA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 SOUTH AFRICA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 SOUTH AFRICA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 SOUTH AFRICA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 SOUTH AFRICA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 SOUTH AFRICA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 113 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 114 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 115 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 SOUTH AFRICA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 SOUTH AFRICA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 119 SOUTH AFRICA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 124 SAUDI ARABIA DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 125 SAUDI ARABIA SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 126 SAUDI ARABIA OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 128 SAUDI ARABIA REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 129 SAUDI ARABIA GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 132 SAUDI ARABIA OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 133 SAUDI ARABIA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 134 SAUDI ARABIA ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 135 SAUDI ARABIA ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 136 SAUDI ARABIA MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 137 SAUDI ARABIA BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 138 SAUDI ARABIA PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 139 SAUDI ARABIA ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 140 SAUDI ARABIA ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 141 SAUDI ARABIA OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 142 SAUDI ARABIA VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 143 SAUDI ARABIA CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 144 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 145 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 146 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 147 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 SAUDI ARABIA TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 149 SAUDI ARABIA ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 150 SAUDI ARABIA LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 151 SAUDI ARABIA INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 152 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 SAUDI ARABIA OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 SAUDI ARABIA RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 U.A.E OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 U.A.E DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 U.A.E SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 U.A.E OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 U.A.E VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 U.A.E REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 U.A.E GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 U.A.E DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 163 U.A.E OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 164 U.A.E OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 165 U.A.E DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 166 U.A.E ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 167 U.A.E ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 168 U.A.E MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 169 U.A.E BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 170 U.A.E PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 171 U.A.E ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 172 U.A.E ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 173 U.A.E OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 174 U.A.E VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 175 U.A.E CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 176 U.A.E OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 177 U.A.E OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 178 U.A.E OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.A.E OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 U.A.E TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 181 U.A.E ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 182 U.A.E LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 183 U.A.E INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 184 U.A.E OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 U.A.E OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 U.A.E RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 EGYPT OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 188 EGYPT DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 189 EGYPT SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 190 EGYPT OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 191 EGYPT VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 192 EGYPT REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 193 EGYPT GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 194 EGYPT DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 195 EGYPT OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 196 EGYPT OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 197 EGYPT DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 198 EGYPT ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 199 EGYPT ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 EGYPT MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 EGYPT BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 EGYPT PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 EGYPT ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 EGYPT ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 EGYPT OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 EGYPT VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 EGYPT CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 EGYPT OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 209 EGYPT OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 210 EGYPT OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 211 EGYPT OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 212 EGYPT TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 EGYPT ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 214 EGYPT LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 215 EGYPT INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 216 EGYPT OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 EGYPT OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 EGYPT RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 219 KUWAIT OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 220 KUWAIT DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 221 KUWAIT SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 222 KUWAIT OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 223 KUWAIT VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 224 KUWAIT REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 225 KUWAIT GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 226 KUWAIT DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 227 KUWAIT OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 228 KUWAIT OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 229 KUWAIT DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 230 KUWAIT ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 231 KUWAIT ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 232 KUWAIT MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 233 KUWAIT BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 234 KUWAIT PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 235 KUWAIT ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 236 KUWAIT ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 237 KUWAIT OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 238 KUWAIT VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 239 KUWAIT CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 240 KUWAIT OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 241 KUWAIT OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 242 KUWAIT OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 KUWAIT OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 244 KUWAIT TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 245 KUWAIT ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 246 KUWAIT LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 247 KUWAIT INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 248 KUWAIT OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 KUWAIT OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 KUWAIT RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 251 ISRAEL OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 ISRAEL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 ISRAEL SURGICAL DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 ISRAEL OPHTHALMIC VISCOELASTIC DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 ISRAEL VITREORETINAL SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 ISRAEL REFRACTIVE SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 ISRAEL GLAUCOMA SURGICAL DEVICES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 ISRAEL DIAGNOSTIC DEVICE IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 ISRAEL OPHTHALMIC ULTRASOUND IMAGING SYSTEMS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 ISRAEL OPHTHALMIC SURGICAL ACCESSORIES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 261 ISRAEL DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 262 ISRAEL ANTI-INFLAMMATION DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 263 ISRAEL ANTI-GLAUCOMA DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 264 ISRAEL MIOTICS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 265 ISRAEL BETA ADRENERGIC ANTAGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 266 ISRAEL PROSTAGLANDIN ANALOGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 267 ISRAEL ALPHA ADRENERGIC AGONISTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 268 ISRAEL ANTI-VEGF DRUGS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 269 ISRAEL OTHERS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 270 ISRAEL VISION CARE PRODUCTS IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 271 ISRAEL CONTACT LENSES IN OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 272 ISRAEL OPHTHALMOLOGY MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 273 ISRAEL OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)
TABLE 274 ISRAEL OPHTHALMOLOGY MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 ISRAEL OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 276 ISRAEL TOPICAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 277 ISRAEL ORAL IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 278 ISRAEL LOCAL OCULAR IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 279 ISRAEL INJECTABLES IN OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 280 ISRAEL OPHTHALMOLOGY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 281 ISRAEL OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 282 ISRAEL RETAIL SALES IN OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 REST OF MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: DBMR POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OPHTHALMIC DISORDERS& INCREASING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 12 THE DEVICE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET FROM 2022 TO 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET
FIGURE 14 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2022
FIGURE 15 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRODUCTS, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRODUCTS, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISEASES, 2022
FIGURE 19 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE ,2022
FIGURE 23 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DRUG TYPE ,2022
FIGURE 27 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY END USER, 2022
FIGURE 35 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 40 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET: SNAPSHOT (2022)
FIGURE 43 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022)
FIGURE 44 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 45 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 46 MIDDLE EAST AND AFRICA OPHTHALMOLOGY MARKET: PRODUCTS (2023-2030)
FIGURE 47 MIDDLE EAST & AFRICA OPHTHALMOLOGY MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
